1. Scrip
  2. >>Business

Roche Partners With UCB On Anti-Tau Alzheimer’s Drug

 
• By Joseph Haas

UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Roche takes another shot in Alzheimer's by licensing UCB anti-tau candidate

Who: Roche/Genentech and UCB

What: Roche obtains worldwide licensing rights to anti-tau UCB0107, with UCB slated to conduct a proof-of-concept study with the antibody in Alzheimer’s, after which

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business